Cargando…

First Efficacy Results of Capecitabine with Anthracycline- and Taxane-Based Adjuvant Therapy in High-Risk Early Breast Cancer: A Meta-Analysis

BACKGROUND: Capecitabine is effective and indicated for the salvage treatment of metastatic breast cancer. Therefore, it is essential to evaluate the efficacy of capecitabine in the adjuvant setting. There have been two large randomized studies to determine whether patients with high-risk early brea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Yiwei, Yin, Wenjin, Zhou, Liheng, Yan, Tingting, Zhou, Qiong, Du, Yueyao, Shen, Zhenzhou, Shao, Zhimin, Lu, Jinsong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292567/ https://www.ncbi.nlm.nih.gov/pubmed/22396769 http://dx.doi.org/10.1371/journal.pone.0032474

Ejemplares similares

A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer
por: Du, Yueyao, et al.
Publicado: (2018)

Postoperative Fever: The Potential Relationship with Prognosis in Node Negative Breast Cancer Patients
por: Yan, Tingting, et al.
Publicado: (2010)

Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials
por: Yin, Wenjin, et al.
Publicado: (2011)

Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane
por: Ahn, Jin-Hee, et al.
Publicado: (2004)

Association of sulfotransferase SULT1A1 with breast cancer risk: a meta-analysis of case-control studies with subgroups of ethnic and menopausal statue
por: Jiang, Yiwei, et al.
Publicado: (2010)

For or against Adjuvant Trastuzumab for pT1a-bN0M0 Breast Cancer Patients with HER2-Positive Tumors: A Meta-Analysis of Published Literatures
por: Zhou, Qiong, et al.
Publicado: (2014)

HIF1α Regulates IL17 Signaling Pathway Influencing Sensitivity of Taxane-Based Chemotherapy for Breast Cancer
por: Dai, Huijuan, et al.
Publicado: (2021)

Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
por: Chen, Wanjing, et al.
Publicado: (2021)

Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients
por: Lin, Yanping, et al.
Publicado: (2009)

Prognostic impact of chemotherapy-induced amenorrhea on premenopausal breast cancer: a meta-analysis of the literature
por: Zhou, Qiong, et al.
Publicado: (2015)

Phase II Study of Pseudomonas aeruginosa-Mannose-Sensitive Hemagglutinin in Combination with Capecitabine for Her-2–Negative Metastatic Breast Cancer Pretreated with Anthracycline and Taxane
por: Lv, Fangfang, et al.
Publicado: (2015)

Downregulated circulating microRNAs after surgery: potential noninvasive biomarkers for diagnosis and prognosis of early breast cancer
por: Wang, Yaohui, et al.
Publicado: (2018)

The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy
por: Hilaj, Erina, et al.
Publicado: (2020)

Clinical significance of locoregional and systemic treatment in operable high-risk breast cancer patients with more than four positive axillary lymph nodes
por: Yin, Kai, et al.
Publicado: (2015)

Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study
por: Zhou, Liheng, et al.
Publicado: (2017)

Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer
por: Vaid, Ashok K., et al.
Publicado: (2020)

Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting
por: Wu, Ziping, et al.
Publicado: (2018)

Combination Chemotherapy of Mitomycin C and Methotrexate Was Effective on Metastatic Breast Cancer Resistant to Eribulin, Vinorelbine, and Bevacizumab after Anthracycline, Taxane, and Capecitabine
por: Tanabe, Masahiko
Publicado: (2016)

Incidence of Chemotherapy-Induced Amenorrhea After Adjuvant Chemotherapy With Taxane and Anthracyclines in Young Patients With Breast Cancer
por: Pourali, Leila, et al.
Publicado: (2013)

Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes
por: Ishida, Takanori, et al.
Publicado: (2008)

Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: a pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology
por: Ntellas, Panagiotis, et al.
Publicado: (2019)

Tumor Glucose and Fatty Acid Metabolism in the Context of Anthracycline and Taxane-Based (Neo)Adjuvant Chemotherapy in Breast Carcinomas
por: Tőkés, Anna Mária, et al.
Publicado: (2022)

Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
por: Park, In Hae, et al.
Publicado: (2019)

Adjuvant therapy of endometrial cancer: “taxane or not taxane, this is the question”
por: Lorusso, Vito, et al.
Publicado: (2019)

Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine
por: Fukuda, Takayo, et al.
Publicado: (2015)

Potential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane
por: Zhou, Li-Yan, et al.
Publicado: (2015)

Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
por: Kaufman, Peter A., et al.
Publicado: (2015)

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis
por: Pajares, Bella, et al.
Publicado: (2013)

Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013)

Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer
por: Veronese, Pedro, et al.
Publicado: (2018)

Successful reduction of alopecia induced by anthracycline and taxane containing adjuvant chemotherapy in breast cancer – clinical evaluation of sensor-controlled scalp cooling
por: Friedrichs, Kay, et al.
Publicado: (2014)

PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)
por: Liu, Minetta C, et al.
Publicado: (2016)

Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy
por: Liao, Yuqian, et al.
Publicado: (2020)

Erratum to: Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013)

A MicroRNA Expression Signature In Taxane-anthracycline-based Neoadjuvant Chemotherapy Response
por: Zheng, Yi, et al.
Publicado: (2015)

Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens
por: Hansen, Ryan N, et al.
Publicado: (2014)

LncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication
por: Sheng, Xiaonan, et al.
Publicado: (2021)

Single-nucleotide polymorphism in microRNA-binding site of SULF1 target gene as a protective factor against the susceptibility to breast cancer: a case-control study
por: Zhou, Qiong, et al.
Publicado: (2016)

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
por: Fernández-Cuesta, Lynnette, et al.
Publicado: (2012)

Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
por: Schreiber, Anna R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l7lorsc0qbcqfqsekfg1q17pp7